{"id":829606,"date":"2025-03-25T13:14:07","date_gmt":"2025-03-25T17:14:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/"},"modified":"2025-03-25T13:14:07","modified_gmt":"2025-03-25T17:14:07","slug":"tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/","title":{"rendered":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan"},"content":{"rendered":"
\n

\n \n <\/p>\n

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) — Tevogen Bio<\/a> (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN<\/a>), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access.<\/p>\n

In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen\u2019s growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readiness. His primary focus will be advancing patient access to the Company\u2019s therapies under development, engaging with government and private payers, and ensuring Health Technology Assessment (HTA) readiness. These initiatives are core to Tevogen\u2019s commercialization strategies, including securing appropriate coding, coverage, and provider reimbursement at launch. Mr. Banko will also lead policy engagement with the current administration to align on shared goals of improving patient accessibility and affordability of emerging medical innovations.<\/p>\n

Mr. Banko brings 30+ years of experience across pharma, medical devices, diagnostics, and hospital finance, with past roles at Cordis Corp, a former Johnson & Johnson (NYSE: JNJ<\/a>) company, and B. Braun Medical Inc. An expert in securing and enhancing market access for innovative technologies, he has successfully leveraged clinical evidence to shape Medicare\u2019s national coverage policies, championed strategic global pricing, and developed initiatives that empower hospitals and physicians to advance the adoption of FDA-approved emerging breakthrough technologies.<\/p>\n

\u201cDavid\u2019s appointment marks an important milestone in Tevogen\u2019s transition toward commercialization readiness,\u201d said Dr. Ryan Saadi, CEO and founder of Tevogen Bio. \u201cCommercial success in today\u2019s healthcare environment requires not only scientific excellence but also clearly defined value propositions for patients, providers, payers, and policymakers alike. David\u2019s deep expertise in market access and health policy will be instrumental in ensuring our innovations are both accessible to patients and deliver lasting value across the healthcare ecosystem,\u201d he added.<\/p>\n

\n About Tevogen Bio<\/strong>\n <\/p>\n

Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature\u2019s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.<\/p>\n

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio\u2019s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. <\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen\u2019s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen\u2019s plans to expand its efforts in artificial intelligence; Tevogen\u2019s ability to develop additional product candidates; Tevogen\u2019s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cgoal,\u201d \u201copportunity,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cfuture,\u201d and similar words and expressions or their opposites. These statements are based on management\u2019s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company\u2019s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.<\/p>\n

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen\u2019s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen\u2019s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen\u2019s limited operating history; and those factors discussed or incorporated by reference in Tevogen\u2019s Annual Report on Form 10-K and subsequent filings with the SEC.<\/p>\n

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com<\/a>\u00a0<\/p>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/a855d43e-e0ad-4e29-b87b-cc5a0981aa66<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) — Tevogen Bio (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen\u2019s growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readiness. His primary focus will be advancing patient access to the Company\u2019s therapies under development, engaging with government and private payers, and ensuring … <\/p>\n

Continue reading “Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829606","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) — Tevogen Bio (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen\u2019s growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readiness. His primary focus will be advancing patient access to the Company\u2019s therapies under development, engaging with government and private payers, and ensuring … Continue reading "Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T17:14:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan\",\"datePublished\":\"2025-03-25T17:14:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/\"},\"wordCount\":1081,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/\",\"name\":\"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=\",\"datePublished\":\"2025-03-25T17:14:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/","og_locale":"en_US","og_type":"article","og_title":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Market Newsdesk","og_description":"WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) — Tevogen Bio (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen\u2019s growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readiness. His primary focus will be advancing patient access to the Company\u2019s therapies under development, engaging with government and private payers, and ensuring … Continue reading \"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T17:14:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan","datePublished":"2025-03-25T17:14:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/"},"wordCount":1081,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/","name":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=","datePublished":"2025-03-25T17:14:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDU5MSM2ODMzNTQ0IzIyODk5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-appoints-david-e-banko-as-global-head-of-government-affairs-and-patient-access-advances-commercialization-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829606"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}